26.5 USD
-0.18 (-0.67%)
Overall XOMAP gets a fundamental rating of 5 out of 10. We evaluated XOMAP against 531 industry peers in the Biotechnology industry. XOMAP has a medium profitability rating, but doesn't score so well on its financial health evaluation. XOMAP is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
XOMAP had positive earnings in the past year.
In the past year XOMAP had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: XOMAP reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: XOMAP reported negative operating cash flow in multiple years.
1.2 Ratios
XOMAP has a Return On Assets of 3.75%. This is amongst the best in the industry. XOMAP outperforms 89.83% of its industry peers.
The Return On Equity of XOMAP (9.14%) is better than 92.66% of its industry peers.
The Return On Invested Capital of XOMAP (3.31%) is better than 90.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.75% | ||
| ROE | 9.14% | ||
| ROIC | 3.31% |
ROA(3y)-14.85%
ROA(5y)-6.52%
ROE(3y)-31.32%
ROE(5y)-15.58%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 20.96%, XOMAP belongs to the best of the industry, outperforming 93.79% of the companies in the same industry.
With an excellent Operating Margin value of 20.92%, XOMAP belongs to the best of the industry, outperforming 95.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.92% | ||
| PM (TTM) | 20.96% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), XOMAP is destroying value.
Compared to 1 year ago, XOMAP has more shares outstanding
The number of shares outstanding for XOMAP has been increased compared to 5 years ago.
The debt/assets ratio for XOMAP is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -4.51, we must say that XOMAP is in the distress zone and has some risk of bankruptcy.
XOMAP has a Altman-Z score of -4.51. This is in the lower half of the industry: XOMAP underperforms 60.83% of its industry peers.
XOMAP has a Debt/Equity ratio of 0.87. This is a neutral value indicating XOMAP is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.87, XOMAP is not doing good in the industry: 75.52% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.87 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.51 |
ROIC/WACC0.37
WACC8.93%
2.3 Liquidity
A Current Ratio of 3.91 indicates that XOMAP has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.91, XOMAP is in line with its industry, outperforming 45.95% of the companies in the same industry.
XOMAP has a Quick Ratio of 3.91. This indicates that XOMAP is financially healthy and has no problem in meeting its short term obligations.
XOMAP has a Quick ratio (3.91) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.91 | ||
| Quick Ratio | 3.91 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 135.71% over the past year.
XOMAP shows a strong growth in Revenue. In the last year, the Revenue has grown by 103.96%.
XOMAP shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.17% yearly.
EPS 1Y (TTM)135.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%144.03%
Revenue 1Y (TTM)103.96%
Revenue growth 3Y-9.28%
Revenue growth 5Y9.17%
Sales Q2Q%29.93%
3.2 Future
Based on estimates for the next years, XOMAP will show a very strong growth in Earnings Per Share. The EPS will grow by 37.32% on average per year.
Based on estimates for the next years, XOMAP will show a very strong growth in Revenue. The Revenue will grow by 34.85% on average per year.
EPS Next Y153.81%
EPS Next 2Y45.01%
EPS Next 3Y37.32%
EPS Next 5YN/A
Revenue Next Year73.56%
Revenue Next 2Y43.09%
Revenue Next 3Y34.85%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 35.33, XOMAP can be considered very expensive at the moment.
XOMAP's Price/Earnings ratio is rather cheap when compared to the industry. XOMAP is cheaper than 92.09% of the companies in the same industry.
When comparing the Price/Earnings ratio of XOMAP to the average of the S&P500 Index (26.49), we can say XOMAP is valued slightly more expensively.
XOMAP is valuated quite expensively with a Price/Forward Earnings ratio of 125.10.
Based on the Price/Forward Earnings ratio, XOMAP is valued cheaply inside the industry as 88.51% of the companies are valued more expensively.
XOMAP's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.69.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 35.33 | ||
| Fwd PE | 125.1 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, XOMAP is valued cheaply inside the industry as 92.28% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 31.99 |
4.3 Compensation for Growth
XOMAP's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
XOMAP's earnings are expected to grow with 37.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.23
PEG (5Y)N/A
EPS Next 2Y45.01%
EPS Next 3Y37.32%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 8.14%, XOMAP is a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 66.57, XOMAP pays a better dividend. On top of this XOMAP pays more dividend than 99.44% of the companies listed in the same industry.
XOMAP's Dividend Yield is rather good when compared to the S&P500 average which is at 2.31.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 8.14% |
5.2 History
XOMAP has been paying a dividend for over 5 years, so it has already some track record.
XOMAP has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years3
5.3 Sustainability
55.43% of the earnings are spent on dividend by XOMAP. This is a bit on the high side, but may be sustainable.
DP55.43%
EPS Next 2Y45.01%
EPS Next 3Y37.32%
XOMA ROYALTY CORP - XOMA 8 5/8 PERP
NASDAQ:XOMAP (12/5/2025, 8:00:02 PM)
26.5
-0.18 (-0.67%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners67.66%
Inst Owner ChangeN/A
Ins Owners1.79%
Ins Owner ChangeN/A
Market Cap328.07M
Revenue(TTM)47.11M
Net Income(TTM)9.87M
Analysts82
Price Target61.78 (133.13%)
Short Float %0.03%
Short Ratio2.09
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 8.14% |
Yearly Dividend0.47
Dividend Growth(5Y)N/A
DP55.43%
Div Incr Years0
Div Non Decr Years3
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1055.58%
Min EPS beat(2)295.48%
Max EPS beat(2)1815.69%
EPS beat(4)3
Avg EPS beat(4)546.36%
Min EPS beat(4)-45.44%
Max EPS beat(4)1815.69%
EPS beat(8)4
Avg EPS beat(8)287.41%
EPS beat(12)5
Avg EPS beat(12)186.43%
EPS beat(16)6
Avg EPS beat(16)118.77%
Revenue beat(2)1
Avg Revenue beat(2)6.32%
Min Revenue beat(2)-20.06%
Max Revenue beat(2)32.7%
Revenue beat(4)2
Avg Revenue beat(4)32.77%
Min Revenue beat(4)-20.06%
Max Revenue beat(4)120.82%
Revenue beat(8)5
Avg Revenue beat(8)16.19%
Revenue beat(12)7
Avg Revenue beat(12)15.39%
Revenue beat(16)8
Avg Revenue beat(16)0.85%
PT rev (1m)14.69%
PT rev (3m)17.33%
EPS NQ rev (1m)-127.67%
EPS NQ rev (3m)-4350%
EPS NY rev (1m)100.31%
EPS NY rev (3m)204.67%
Revenue NQ rev (1m)-9.59%
Revenue NQ rev (3m)-9.59%
Revenue NY rev (1m)-6.18%
Revenue NY rev (3m)-2.78%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 35.33 | ||
| Fwd PE | 125.1 | ||
| P/S | 6.96 | ||
| P/FCF | N/A | ||
| P/OCF | 59.99 | ||
| P/B | 3.04 | ||
| P/tB | 5.17 | ||
| EV/EBITDA | 31.99 |
EPS(TTM)0.75
EY2.83%
EPS(NY)0.21
Fwd EY0.8%
FCF(TTM)-1.19
FCFYN/A
OCF(TTM)0.44
OCFY1.67%
SpS3.81
BVpS8.72
TBVpS5.12
PEG (NY)0.23
PEG (5Y)N/A
Graham Number12.13
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.75% | ||
| ROE | 9.14% | ||
| ROCE | 4.2% | ||
| ROIC | 3.31% | ||
| ROICexc | 4.14% | ||
| ROICexgc | 5.42% | ||
| OM | 20.92% | ||
| PM (TTM) | 20.96% | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-14.85%
ROA(5y)-6.52%
ROE(3y)-31.32%
ROE(5y)-15.58%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.18
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.87 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 7.77 | ||
| Cap/Depr | 880.03% | ||
| Cap/Sales | 42.84% | ||
| Interest Coverage | 0.83 | ||
| Cash Conversion | 45.03% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.91 | ||
| Quick Ratio | 3.91 | ||
| Altman-Z | -4.51 |
F-Score6
WACC8.93%
ROIC/WACC0.37
Cap/Depr(3y)7738.51%
Cap/Depr(5y)4653.1%
Cap/Sales(3y)108.05%
Cap/Sales(5y)64.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)135.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%144.03%
EPS Next Y153.81%
EPS Next 2Y45.01%
EPS Next 3Y37.32%
EPS Next 5YN/A
Revenue 1Y (TTM)103.96%
Revenue growth 3Y-9.28%
Revenue growth 5Y9.17%
Sales Q2Q%29.93%
Revenue Next Year73.56%
Revenue Next 2Y43.09%
Revenue Next 3Y34.85%
Revenue Next 5YN/A
EBIT growth 1Y152.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year158.48%
EBIT Next 3Y50.21%
EBIT Next 5YN/A
FCF growth 1Y55.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y130.18%
OCF growth 3YN/A
OCF growth 5YN/A
XOMA ROYALTY CORP - XOMA 8 5/8 PERP / XOMAP FAQ
What is the ChartMill fundamental rating of XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) stock?
ChartMill assigns a fundamental rating of 5 / 10 to XOMAP.
What is the valuation status for XOMAP stock?
ChartMill assigns a valuation rating of 4 / 10 to XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP). This can be considered as Fairly Valued.
What is the profitability of XOMAP stock?
XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) has a profitability rating of 5 / 10.
What are the PE and PB ratios of XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) stock?
The Price/Earnings (PE) ratio for XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) is 35.33 and the Price/Book (PB) ratio is 3.04.
What is the earnings growth outlook for XOMA ROYALTY CORP - XOMA 8 5/8 PERP?
The Earnings per Share (EPS) of XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) is expected to grow by 153.81% in the next year.